Startups
We are a clinical-stage biopharmaceutical company developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology, and cardiology. We work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to deliver important medicines to patients, and relentlessly execute until it’s done.
With our new Work Together, Live Wherever approach, we have employees across the USA and Switzerland, with hub offices in San Diego, CA; Boston, MA; Park City, UT; and Zug, Switzerland.
Arena - Care More. Act Differently.
Community guidelines: bit.ly/3hDaRPS
With our new Work Together, Live Wherever approach, we have employees across the USA and Switzerland, with hub offices in San Diego, CA; Boston, MA; Park City, UT; and Zug, Switzerland.
Arena - Care More. Act Differently.
Community guidelines: bit.ly/3hDaRPS
Overview
Location
United States, California, Sorrento Valley
Employees
201-500
Total raised
$33M
Founded date
1997
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 24
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 15, 2022 | Pfizer’s announced purchase of Arena Pharmaceuticals exemplifies a satisfactory acquisition within the CBD medical treatment industry | Pfizer’s announced purchase of Arena Pharmaceuticals exemplifies a satisfactory acquisition within the CBD medical treatment industry Tue, Feb 15, 2022 11:19 CET Report this content CS MEDICA A/S (”CS MEDICA” or the ”Company”) see a strateg... |
| Dec 13, 2021 | Arena Pharmaceuticals soars 97% as Pfizer to spend $6.7 billion to buy ulcerative colitis drug developer | Arena Pharma surged 97% on Monday as Pfizer said it will buy the drug developer in a $6.7 billion deal. Pfizer will pay $100 in cash for all of Arena's outstanding shares, a deal approved by both boards. Advertisement Shares of Arena Pharma... |
| Dec 13, 2021 | Pfizer : Event Announcement (PDF 97 KB) (opens in new window) | For Immediate Release Pfizer Media Contact: +1 (212) 733-1226 December 13, 2021 [email protected] Pfizer Investor +1 (212) 733-4848 Contact: [email protected] Arena Patrick Malloy Pharmaceuticals, Inc. Vice President, Investor Rel... |
| Dec 13, 2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday, Term Sheeters. Paid Content PwC is teaching executives to lead with trust. Here’s w... |
| Dec 13, 2021 | Pfizer to Buy Arena Pharmaceuticals at $6.7 Billion Value | By Matt Grossman Pfizer Inc. plans to acquire Arena Pharmaceuticals Inc. in a deal valuing Arena at $6.7 billion, the companies said Monday. Pfizer plans to buy Arena's outstanding shares for $100 a share in an all-cash transaction. Arena's... |
| Dec 13, 2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday, Term Sheeters. Paid Content Keeping file transfers secure and simple in the cloud F... |
| Jun 29, 2021 | Lyfebulb : and Arena Pharmaceuticals Announce the Finalists for the 2021 Imagining Life Without Limits - An Inflammatory Bowel Disease Innovation Challenge | NEW YORK, June 29, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform and innovation accelerator that connects patients with one another and with industry to support user-driven innovation, and Arena Pharmaceuticals, a company fo... |
| Nov 10, 2020 | ARENA PHARMACEUTICALS, INC. Arena Pharmaceuticals : Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial | SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S... |
| Nov 10, 2020 | Arena Pharmaceuticals : Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial | SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S... |
Show more
Reviews 0
FAQ about Arena Pharmaceuticals, Inc.
When was Arena Pharmaceuticals, Inc. founded?
Arena Pharmaceuticals, Inc. was founded in 1997.
How much funding has Arena Pharmaceuticals, Inc. raised?
Arena Pharmaceuticals, Inc. has raised $33M in total across 1 funding round.
What has the press written about Arena Pharmaceuticals, Inc.?
Parsers VC has collected 24 articles mentioning Arena Pharmaceuticals, Inc., among them “Pfizer’s announced purchase of Arena Pharmaceuticals exemplifies a satisfactory acquisition within the CBD medical treatment industry” (Feb 15, 2022) and “Arena Pharmaceuticals soars 97% as Pfizer to spend $6.7 billion to buy ulcerative colitis drug developer” (Dec 13, 2021).
Is Arena Pharmaceuticals, Inc. still active?
Yes, Arena Pharmaceuticals, Inc. is active; its latest activity on Parsers VC dates from Oct 7, 2024.